Benny Lava schreef op 18 augustus 2015 20:04:
Based on industry reports, TiGenix estimates perianal fistulas in Crohn's disease patients to represent a market opportunity in excess of
EUR 2 billion in Europe and the US combined. TiGenix is currently evaluating partnering options for the programme.
So hey, wat een bedragen.